NEJM:埃博拉病毒幸存者后遗症分析

2019-03-07 xing.T 网络

由此可见,所有参与者都出现了相对较高的症状负担,但某些症状和检查结果在幸存者中更常见。除葡萄膜炎外,两组患者在随访期间患病率均有所下降。精液中的病毒RNA持续时间最多40个月。

埃博拉病毒病(EVD)幸存者报告了多种健康问题。在没有对照组进行分析的情况下将这些问题归因于疾病是极为困难的。

近日,顶级医学期刊NEJM上发表了一篇研究文章,研究人员招募了一组EVD幸存者及其密切接触者,并前瞻性地收集了有关症状、体格检查结果和实验室检查结果的数据。一部分参与者接受了眼科检查,并确定了来自幸存者精液样品中埃博拉病毒(EBOV)RNA的持久性。

该研究共招募了966名EBOV抗体阳性幸存者和2350名抗体阴性密切接触者(对照者),并且90%的这些参与者被随访了12个月。在入组时(基线就诊的中位时间为症状发作后358天),幸存者中报告的6种症状明显多于对照组:尿频(14.7% vs. 3.4%)、头痛(47.6% vs. 35.6%)、疲劳(18.4% vs. 6.3%)、肌肉疼痛(23.1% vs. 10.1%)、记忆力减退(29.2% vs. 4.8%)和关节疼痛(47.5% vs. 17.5%)。在检查中,比对照组更多的幸存者有异常的腹部、胸部、神经和肌肉骨骼体征和葡萄膜炎。除葡萄膜炎外(入组时患病率为26.4% vs. 12.1%;第1年为33.3% vs. 15.4%),这些疾病的患病率在随访期间均有所下降。幸存者中大多数症状、神经系统体征和葡萄膜炎的发生率高于对照组。在30%的受试幸存者的精液样本中检测到EBOV的RNA,最长时间从发病到40个月。 

由此可见,所有参与者都出现了相对较高的症状负担,但某些症状和检查结果在幸存者中更常见。除葡萄膜炎外,两组患者在随访期间患病率均有所下降。精液中的病毒RNA持续时间最多40个月。 

原始出处:

The PREVAIL III Study Group,et al.A Longitudinal Study of Ebola Sequelae in Liberia.NEJM.2019.https://www.nejm.org/doi/full/10.1056/NEJMoa1805435

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650378, encodeId=6c4616503e8aa, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Dec 29 08:23:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296482, encodeId=bc7d12964823c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418790, encodeId=3b051418e9095, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362234, encodeId=403c362234a0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Fri Mar 08 09:08:35 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362181, encodeId=ae0636218121, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Mar 07 09:29:51 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650378, encodeId=6c4616503e8aa, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Dec 29 08:23:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296482, encodeId=bc7d12964823c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418790, encodeId=3b051418e9095, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362234, encodeId=403c362234a0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Fri Mar 08 09:08:35 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362181, encodeId=ae0636218121, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Mar 07 09:29:51 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650378, encodeId=6c4616503e8aa, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Dec 29 08:23:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296482, encodeId=bc7d12964823c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418790, encodeId=3b051418e9095, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362234, encodeId=403c362234a0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Fri Mar 08 09:08:35 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362181, encodeId=ae0636218121, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Mar 07 09:29:51 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-03-08 huirong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1650378, encodeId=6c4616503e8aa, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Dec 29 08:23:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296482, encodeId=bc7d12964823c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418790, encodeId=3b051418e9095, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362234, encodeId=403c362234a0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Fri Mar 08 09:08:35 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362181, encodeId=ae0636218121, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Mar 07 09:29:51 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-03-08 183****7028

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1650378, encodeId=6c4616503e8aa, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Dec 29 08:23:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296482, encodeId=bc7d12964823c, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418790, encodeId=3b051418e9095, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri Mar 08 23:23:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362234, encodeId=403c362234a0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Fri Mar 08 09:08:35 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362181, encodeId=ae0636218121, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Mar 07 09:29:51 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-03-07 明月清辉

    谢谢分享,学习了

    0

相关威廉亚洲官网

Nature Microbiology:欣喜!广谱埃博拉病毒疫苗新突破

Nature Microbiology》发文,联合课题组成功研制出新型埃博拉抗体,这种抗体可用于多种埃博拉病毒治疗。

Protein & Cell:武汉病毒所埃博拉病毒糖蛋白致病效应研究取得进展

近日,中国科学院武汉病毒研究所王华林学科组在埃博拉病毒糖蛋白致病效应及其实验模型的研究中取得新进展,部分成果在线发表在Protein & Cell上。

针对埃博拉病毒的DNA疫苗在临床前研究中显示出长期疗效

发表在《Journal of Infectious Diseases》上的临床前研究数据表明,一种新型合成DNA疫苗可以完全防止埃博拉病毒的感染。

Blood:为什么感染埃博拉病毒会增加患淋巴瘤的风险?

埃博拉病毒(EBV)在大部分人类宿主的B淋巴细胞中持续存在,与多种B细胞淋巴瘤相关。潜伏感染期,EBV翻译合成隐匿膜蛋白2A(LMP2A)来模拟宿主B细胞受体(BCR)的信号通路,以此维持B细胞存活。在活体内研究LMP2A在淋巴瘤发生过程的作用,研究人员发现在转基因小鼠模型中,LMP2A通过使B细胞逃逸p53信号通路介导的MYC-诱导的细胞凋亡,从而使MYC所驱动的淋巴瘤快速发生。

埃博拉病毒的新克星:高剂量的法匹拉韦

尽管近年来埃博拉病毒疫情反复爆发,受埃博拉病毒感染的患者并没有得到有效的治疗,以至于疫情通常会导致约50%感染者死亡。近日,一项新的研究显示,高剂量的法匹拉韦显著延长了埃博拉病毒感染的非人类灵长类动物的存活率。

荐读|人体细胞中发现抗埃博拉病毒蛋白!治疗肾性贫血新药罗沙司他胶囊获批上市!

行业新闻 1.陈冯富珍、钟南山、屠呦呦被授予改革先锋称号 12月18日,中共中央、国务院召开庆祝改革开放40周年大会,会上宣读了《中共中央 国务院关于表彰改革开放杰出贡献人员的决定》,授予于敏等100名同志改革先锋称号,颁授改革先锋奖章,其中陈冯富珍、钟南山、屠呦呦3人来自卫生健康领域。(健康报)